NasdaqCM:JBIOBiotechs
Jade Biosciences Reshapes Clinical Leadership As Valuation Debate Persists
Jade Biosciences (NasdaqCM: JBIO) appointed Edward R. Conner, M.D. as Chief Medical Officer.
The company elevated Andrew King, M.D., Ph.D. to President, Research & Development.
These leadership changes focus on clinical development, regulatory strategy, and R&D continuity for Jade's autoimmune pipeline.
Jade Biosciences, listed on NasdaqCM under the ticker JBIO, is focused on developing therapies for autoimmune conditions, an area that continues to attract capital and partnerships across...